Navigation Links
Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
Date:1/22/2009

lood sugar. Initial clinical studies of trodusquemine in obese and overweight subjects has provided early indicators of weight loss and improved glucose control. These results confirm previous work in animal models which demonstrated significant weight loss without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
4. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
5. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
6. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
7. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
10. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... today announced that it will release Second Quarter ... 3rd, 2015. AcelRx management will host an investment-community ... p.m. Pacific Time) on Aug 3rd, 2015 to ...
(Date:7/29/2015)... , NEW YORK and ... 2015  CMC Biologics, a global leader in ... Vision Development Corporation (River Vision), a private company ... entered into an agreement for the process transfer ... recombinant monoclonal antibody targeting insulin-like growth factor 1 ...
(Date:7/28/2015)... July 28, 2015  Insulet Corporation (NASDAQ: PODD ... its OmniPod ® Insulin Management System, today announced ... to Insulet,s Board of Directors. Dr. Hopfield ... to the Insulet Board. She currently serves as the ... Center, the world,s largest diabetes research center, diabetes clinic, ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 2CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 3Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3
(Date:7/29/2015)... ... 29, 2015 , ... CrossFit 269, offering a nationally franchised ... Strength & Conditioning. , The name change coincides with the release of its ... center over the past three years,” according to Jack Kelly, the center’s owner ...
(Date:7/29/2015)... , ... July 29, 2015 , ... For the second ... be featured in the list of the 50 fastest growing companies in Jacksonville. This ... the business community. On July 16th, a team of Vast Bridges staffers were on ...
(Date:7/29/2015)... ... 2015 , ... CanAm Enterprises, LLC (“CanAm”) is thrilled to announce that more ... have been granted to investors in four different CanAm EB-5 projects -- the Sony ... Philadelphia, and the Valley Forge Convention Center project in CanAm’s regional center in partnership ...
(Date:7/29/2015)... ... , ... A June 10, 2015 article from the News-Press, entitled " It's ... having regular skin cancer screenings from an early age. Skin cancer can strike at ... early, skin cancer is rarely fatal; however, if left alone for too long, the ...
(Date:7/29/2015)... ... , ... Several years ago, in order to be in the strongest position ... proactive stance and began planning the Children’s Village consisting of six homes. , Two ... the third home. , “We are very pleased to have received the $500,000 grant ...
Breaking Medicine News(10 mins):Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3
... Indication for Bothersome Vaginal Symptom Associated,With Menopause, ... Cream 0.5 g has been approved by the ... indication and a new less,frequent twice-weekly dosing regimen ... intercourse) announced Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ...
... non-small cell lung cancer whose disease has progressed ... shrinkage and a longer interval before cancer progression ... therapy, according to a study presented at the ... by ASTRO, ASCO, IASLC and the University of ...
... CHICAGO - The four drug-combination of carboplatin and paclitaxel, ... is safe and may improve survival for patients with ... led by The University of Texas M. D. Anderson ... of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, ...
... HealthCentral,( http://www.HealthCentral.com ) the leading collection ... today announced a,broad initiative to sell advertising ... will welcome partners on a,non-exclusive basis and ... traffic in,third party rankings., "We are ...
... Texas, Nov. 13 Wound Care,Innovations, LLC, a ... WNDM), announced today the 510k clearance of a ... technology., The new addition to our product ... properties of polysulfated,glycosaminoglycan (PSGAG) and will initially be ...
... 13 MedQuist Inc.,(Nasdaq: MEDQ ), ... and services, and Clario Medical Imaging Inc. ... zVision(TM) software with MedQuist,s,SpeechQ for Radiology(TM) speech ... point to manage workflow and dictate using ...
Cached Medicine News:Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Novel 4-drug combination proves safe for lung cancer treatment 2Health News:HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences 2Health News:Wound Management Technologies, Inc. Announces FDA Clearance of 510k 2Health News:Wound Management Technologies, Inc. Announces FDA Clearance of 510k 3Health News:MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 2Health News:MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: